In inflammatory breast cancer, the CD44+/CD24−/low cancer stem cell subset harbors higher levels of CYP1B1 [48], and 4-OHE2 treatment induces anchorage-independent growth of mammary epithelial cells [23]. Here, CYP1B1 is linked to inflammatory breast carcinoma.